Your browser doesn't support javascript.
loading
Key summary of German national guideline for adult patients with nosocomial pneumonia- Update 2024 Funding number at the Federal Joint Committee (G-BA): 01VSF22007.
Rademacher, Jessica; Ewig, Santiago; Grabein, Béatrice; Nachtigall, Irit; Abele-Horn, Marianne; Deja, Maria; Gaßner, Martina; Gatermann, Sören; Geffers, Christine; Gerlach, Herwig; Hagel, Stefan; Heußel, Claus Peter; Kluge, Stefan; Kolditz, Martin; Kramme, Evelyn; Kühl, Hilmar; Panning, Marcus; Rath, Peter-Michael; Rohde, Gernot; Schaaf, Bernhard; Salzer, Helmut J F; Schreiter, Dierk; Schweisfurth, Hans; Unverzagt, Susanne; Weigand, Markus A; Welte, Tobias; Pletz, Mathias W.
Afiliação
  • Rademacher J; Department of Respiratory Medicine and Infectious Diseases, German Centre of Lung Research (DZL), Hannover Medical School, Hannover, Germany. rademacher.jessica@mh-hannover.de.
  • Ewig S; Department of Respiratory and Infectious Diseases, Thoraxzentrum Ruhrgebiet, EVK Herne and Augusta-Kranken-Anstalt Bochum, Bochum, Germany.
  • Grabein B; LMU Hospital, Clinical Microbiology and Hospital Hygiene, Munich, Germany.
  • Nachtigall I; Division of Infectious Diseases and Infection Prevention, Helios Hospital Emil-Von-Behring, Berlin, Germany.
  • Abele-Horn M; Institute for Hygiene and Microbiology, University of Würzburg, Würzburg, Germany.
  • Deja M; Department of Anesthesiology and Intensive Care Medicine, University Medical Center Schleswig-Holstein, Berlin, Lübeck, Germany.
  • Gaßner M; Department of Anaesthesiology and Intensive Care Medicine, Charité, Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
  • Gatermann S; National Reference Centre for Multidrug-Resistant Gram-Negative Bacteria, Department of Medical Microbiology, Ruhr-University Bochum, Bochum, Germany.
  • Geffers C; Charité, Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Institute of Hygiene and Environmental Medicine, Berlin, Germany.
  • Gerlach H; Department for Anaesthesia, Intensive Care Medicine and Pain Management, Vivantes-Klinikum Neukoelln, Berlin, Germany.
  • Hagel S; Institute for Infectious Diseases and Infection Control, Jena University Hospital-Friedrich Schiller University Jena, Jena, Germany.
  • Heußel CP; Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Kluge S; Department of Intensive Care, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Kolditz M; Division of Pulmonology, Medical Department 1, University Hospital of TU Dresden, Dresden, Germany.
  • Kramme E; Department of Infectious Diseases and Microbiology, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, Germany.
  • Kühl H; Department of Radiology, St. Bernhard-Hospital Kamp-Lintfort, Bürgermeister-Schmelzing-Str. 90, 47475, Kamp-Lintfort, Germany.
  • Panning M; Institute of Virology, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Rath PM; Institute for Medical Microbiology, University Medicine Essen, Essen, Germany.
  • Rohde G; Department of Respiratory Medicine, Goethe University Frankfurt, University Hospital, Frankfurt/Main, Germany.
  • Schaaf B; Department of Respiratory Medicine and Infectious Diseases, Klinikum Dortmund, Dortmund, Germany.
  • Salzer HJF; Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine-Pneumology, Kepler University Hospital, Medical Faculty, Johannes Kepler University, Linz, Austria.
  • Schreiter D; Department of Intensive Care Medicine, Helios Park Clinic, Leipzig, Germany.
  • Schweisfurth H; Institute for Pulmonary Research (IPR), Cottbus, Germany.
  • Unverzagt S; Institute of General Practice and Family Medicine, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
  • Weigand MA; Department of Anesthesiology, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
  • Welte T; Department of Respiratory Medicine and Infectious Diseases, German Centre of Lung Research (DZL), Hannover Medical School, Hannover, Germany.
  • Pletz MW; Institute for Infectious Diseases and Infection Control, Jena University Hospital-Friedrich Schiller University Jena, Jena, Germany.
Infection ; 2024 Aug 08.
Article em En | MEDLINE | ID: mdl-39115698
ABSTRACT

PURPOSE:

This executive summary of a German national guideline aims to provide the most relevant evidence-based recommendations on the diagnosis and treatment of nosocomial pneumonia.

METHODS:

The guideline made use of a systematic assessment and decision process using evidence to decision framework (GRADE). Recommendations were consented by an interdisciplinary panel. Evidence analysis and interpretation was supported by the German innovation fund providing extensive literature searches and (meta-) analyses by an independent methodologist. For this executive summary, selected key recommendations are presented including the quality of evidence and rationale for the level of recommendation.

RESULTS:

The original guideline contains 26 recommendations for the diagnosis and treatment of adults with nosocomial pneumonia, thirteen of which are based on systematic review and/or meta-analysis, while the other 13 represent consensus expert opinion. For this key summary, we present 11 most relevant for everyday clinical practice key recommendations with evidence overview and rationale, of which two are expert consensus and 9 evidence-based (4 strong, 5 weak and 2 open recommendations). For the management of nosocomial pneumonia patients should be divided in those with and without risk factors for multidrug-resistant pathogens and/or Pseudomonas aeruginosa. Bacterial multiplex-polymerase chain reaction (PCR) should not be used routinely. Bronchoscopic diagnosis is not considered superior to´non-bronchoscopic sampling in terms of main outcomes. Only patients with septic shock and the presence of an additional risk factor for multidrug-resistant pathogens (MDRP) should receive empiric combination therapy. In clinically stabilized patients, antibiotic therapy should be de-escalated and focused. In critically ill patients, prolonged application of suitable beta-lactam antibiotics should be preferred. Therapy duration is suggested for 7-8 days. Procalcitonin (PCT) based algorithm might be used to shorten the duration of antibiotic treatment. Patients on the intensive care unit (ICU) are at risk for invasive pulmonary aspergillosis (IPA). Diagnostics for Aspergillus should be performed with an antigen test from bronchial lavage fluid.

CONCLUSION:

The current guideline focuses on German epidemiology and standards of care. It should be a guide for the current treatment and management of nosocomial pneumonia in Germany.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article